Interim report January - March 2021: Vicore Pharma Holding AB

By Vicore Pharma Holding Ab7 days ago

GOTHENBURG, Sweden, May 5, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2021.

Important events during the first quarter

  • In February, Vicore completed a directed share issue raising 336 MSEK. The share issue was approved at an Extraordinary General Meeting in March.
  • In March, Vicore reported top-line data from the mechanistic phase II study in systemic sclerosis and Raynaud's phenomenon (SSc) showing that C21 increased bloodflow in fibrotic tissue.

Important events after the period

  • In May, Vicore announced that it has entered into a collaboration agreement with Alex Therapeutics for the development of a digital therapeutic (DTx) for patients living with idiopathic pulmonary fibrosis (IPF).

Financial overview for the period

January 1 March 31, 2021

  • Net sales amounted to 0.0 MSEK (0.0)
  • The operating loss was -47.5 MSEK (-28.8)
  • Loss for the period amounted to -48.1 MSEK (-28.4)
  • Loss per share, before and after dilution, was -0.76 SEK (-0.56)
  • On March 31, 2021, cash and cash equivalents and short-term investments amounted to 589.9 MSEK (318.7 MSEK as of December 31, 2020)

Continue read on